Search results for "oligonucleotides" in Articles / App Notes
Article
Transformative Medicines Challenge FDA and Manufacturers
Guynh Nhu Nguyes, associate director for human factors in the Division of Medication Error Prevention and Analysis in the Center for Drug Evaluation and Research (CDER), outlined at the oligonucleotid…
Article
Are you ready to optimize your oligo synthesis?
In this white paper, we share what we learned in our four decades of experience in flow-through synthesis of oligo manufacturing.
Read it now to explore five key areas in your oligonucleotid…
Article
How can you harness the potential of nucleic acid therapeutics?
At Cytiva, the new team is here to support you. We can help you throughout the
development of your manufacturing workflow for oligonucleotides
and the purification of mRNA drug subs…
Article
Top Process Development Trends for 2021 and a Look into 2022
…iruses for delivery; oligo-based therapeutics such as anti-sense DNA, siRNA, mRNA, splice-switching oligonucleotides, and immune-stimulatory oligonucleotides; extracellular vesicles and exosomes such…
Article
A Look at the Affinity Chromatography Landscape
Other libraries consist of polypetides produced by means of phage display and/or ribosome display and aptamers, short single-stranded RNA or DNA oligonucleotides that spontaneously fold into structure…
Article
Automated Concentration and Diafiltration of Multiple siRNA Samples
PROCESS DESCRIPTION
The production of RNA oligonucleotides in the process workflow begins with chemical synthesis using the ÄKTAoligopilot platform to create single-stranded RNA (ssRNA)…
Article
Ready for a strong start in oligo manufacturing?
Are you interested in manufacturing your own oligonucleotide therapeutics but don’t know how to start? Or are you already manufacturing your own oligos but are running into challenges? If so, …
Article
Top Process Development Trends for 2022 and a Look into 2023
FDA approved 37 drugs in 2022, within the normal range for the past decade or so. The European Medicines Agency (EMA) was even more successful—approving a record 55 therapies. More than half of thes…
Article
Future Downstream Process Development Solutions for Advanced Therapies
downstream
Click here to view more Industry Leader Q&As >>
Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva, provides insight into solutions for ad…
Article
Gene Therapies Push Viral Vector Production
“Apart from plasmids there are liposomes, lipoplexes, polyplexes, and oligonucleotides [that can be used] as non-viral modes of gene delivery.”
Vicaire also notes that using non-viral vehicles …